Literature DB >> 4209875

Editorial: Facial hyperkinesis.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4209875      PMCID: PMC1613071     

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  12 in total

1.  Treatment of essential blepharospasm with a frontalis sling.

Authors:  A M Putterman; M Urist
Journal:  Arch Ophthalmol       Date:  1972-09

2.  Reserpine: cause and treatment of oral-facial dyskinesia.

Authors:  S M Wolf
Journal:  Bull Los Angeles Neurol Soc       Date:  1973-04

3.  Complications in surgery for blepharospasm.

Authors:  R K Dortzbach
Journal:  Am J Ophthalmol       Date:  1973-01       Impact factor: 5.258

4.  Spontaneous oral-facial dyskinesia.

Authors:  P H Altrocchi
Journal:  Arch Neurol       Date:  1972-06

5.  Neuropathological findings in three cases of persistent dyskinesia following phenothiazine medication.

Authors:  R Hunter; W Blackwood; M C Smith; J N Cumings
Journal:  J Neurol Sci       Date:  1968 Sep-Oct       Impact factor: 3.181

6.  [Effect of dioxyphenylalanine (L-DOPA) on extrapyramidal motoric hyperkineses after prolonged neuroleptic therapy].

Authors:  H Hippius; G Logemann
Journal:  Arzneimittelforschung       Date:  1970-07

7.  A study of biogenic amine metabolites in the cerebrospinal fluid and urine of monkeys with chlorpromazine-induced dyskinesia.

Authors:  F S Messiha
Journal:  J Neurol Sci       Date:  1974-01       Impact factor: 3.181

8.  Essential (idiopathic) blepharospasm.

Authors:  S A Fox
Journal:  Arch Ophthalmol       Date:  1966-09

9.  Differential section of the facial nerve for blepharospasm.

Authors:  D H Reynolds; J L Smith; T J Walsh
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1967 Jul-Aug

10.  Analysis of L-dopa induced dyskinesias in 51 patients with Parkinsonism.

Authors:  R J Mones; T S Elizan; G J Siegel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1971-12       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.